ATE244564T1 - Felbamat-derivate - Google Patents

Felbamat-derivate

Info

Publication number
ATE244564T1
ATE244564T1 AT00907199T AT00907199T ATE244564T1 AT E244564 T1 ATE244564 T1 AT E244564T1 AT 00907199 T AT00907199 T AT 00907199T AT 00907199 T AT00907199 T AT 00907199T AT E244564 T1 ATE244564 T1 AT E244564T1
Authority
AT
Austria
Prior art keywords
derivatives
felbamate
felbamat
treat
epilepsy
Prior art date
Application number
AT00907199T
Other languages
English (en)
Inventor
Timothy L Macdonald
Thomas A Miller
Charles D Thompson
Christine M Dieckhaus
Original Assignee
Univ Virginia
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Virginia filed Critical Univ Virginia
Application granted granted Critical
Publication of ATE244564T1 publication Critical patent/ATE244564T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • C07D265/04—1,3-Oxazines; Hydrogenated 1,3-oxazines
    • C07D265/06—1,3-Oxazines; Hydrogenated 1,3-oxazines not condensed with other rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
    • C07C271/06—Esters of carbamic acids
    • C07C271/08—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms
    • C07C271/10—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C271/12—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms to hydrogen atoms or to carbon atoms of unsubstituted hydrocarbon radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/08—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D263/16—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D263/18—Oxygen atoms
    • C07D263/20—Oxygen atoms attached in position 2
    • C07D263/24—Oxygen atoms attached in position 2 with hydrocarbon radicals, substituted by oxygen atoms, attached to other ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • C07D265/04—1,3-Oxazines; Hydrogenated 1,3-oxazines
    • C07D265/06—1,3-Oxazines; Hydrogenated 1,3-oxazines not condensed with other rings
    • C07D265/08—1,3-Oxazines; Hydrogenated 1,3-oxazines not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D265/10—1,3-Oxazines; Hydrogenated 1,3-oxazines not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with oxygen atoms directly attached to ring carbon atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Cardiology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurology (AREA)
  • Vascular Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Compounds Of Iron (AREA)
  • Hard Magnetic Materials (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Paper (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
AT00907199T 1999-02-09 2000-02-08 Felbamat-derivate ATE244564T1 (de)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US11925499P 1999-02-09 1999-02-09
US13688199P 1999-06-01 1999-06-01
US13720499P 1999-06-02 1999-06-02
PCT/US2000/003147 WO2000047202A1 (en) 1999-02-09 2000-02-08 Felbamate derived compounds

Publications (1)

Publication Number Publication Date
ATE244564T1 true ATE244564T1 (de) 2003-07-15

Family

ID=27382271

Family Applications (1)

Application Number Title Priority Date Filing Date
AT00907199T ATE244564T1 (de) 1999-02-09 2000-02-08 Felbamat-derivate

Country Status (13)

Country Link
US (3) US6538024B1 (de)
EP (1) EP1156798B1 (de)
JP (1) JP2002536409A (de)
AT (1) ATE244564T1 (de)
AU (1) AU771936B2 (de)
CA (1) CA2360258A1 (de)
DE (1) DE60003791T2 (de)
DK (1) DK1156798T3 (de)
ES (1) ES2197078T3 (de)
MX (1) MXPA01007968A (de)
NZ (1) NZ513319A (de)
PT (1) PT1156798E (de)
WO (1) WO2000047202A1 (de)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2407697A1 (en) * 2000-05-05 2001-11-15 University Of Virginia Patent Foundation Felbamate derived compounds
MXPA03003677A (es) * 2000-10-25 2004-05-04 Univ Virginia Compuestos derivados de felbamato sustituidos.
US20030166648A1 (en) * 2002-11-01 2003-09-04 Macdonald Timothy L Felbamate derived compounds
JP4620734B2 (ja) 2004-06-08 2011-01-26 ランクセス・ドイチュランド・ゲーエムベーハー 改良された流動性を有するポリアミド成形用組成物
JP4732457B2 (ja) 2004-06-08 2011-07-27 ランクセス・ドイチュランド・ゲーエムベーハー 熱可塑性ポリエステルをベースとする改良された流動性を有する成形用組成物
PT1809273E (pt) * 2004-09-16 2010-05-10 Janssen Pharmaceutica Nv Utililização de 2-fenil-1,2-etanodiol-(di)carbamatos para tratamento de epileptogénese
JP2008538565A (ja) * 2005-04-21 2008-10-30 メドポイント ヘルスケア インコーポレイテッド ジカルバメート化合物の合成法およびその作製における中間体
US20070021501A1 (en) * 2005-07-12 2007-01-25 Twyman Roy E Methods of treating epileptogenesis
DE102006020984A1 (de) * 2006-05-04 2007-11-08 Lanxess Deutschland Gmbh Leichtbauteil in Hybridbauweise
DE102007006493A1 (de) * 2007-02-09 2008-08-14 Lanxess Deutschland Gmbh Leichtbauteil in Hybridbauweise
WO2009129181A1 (en) * 2008-04-14 2009-10-22 Concert Pharmaceuticals Inc. Propanediol-dicarbamate derivatives
DE102008032205A1 (de) 2008-07-09 2010-01-14 Lanxess Deutschland Gmbh Fließverbesserte Thermoplasten
DE202008015391U1 (de) 2008-11-19 2010-04-22 Lanxess Deutschland Gmbh Türen- und Klappenstrukturen
DE202008015399U1 (de) 2008-11-19 2010-04-08 Lanxess Deutschland Gmbh Dachstruktur
DE202008015395U1 (de) 2008-11-19 2010-04-22 Lanxess Deutschland Gmbh Vorderwagenstruktur
DE102008058224A1 (de) * 2008-11-19 2010-05-20 Lanxess Deutschland Gmbh Leichtbauteil in Hybridbauweise
DE202008015397U1 (de) 2008-11-19 2010-04-22 Lanxess Deutschland Gmbh Säulenstruktur
DE102008058225A1 (de) * 2008-11-19 2010-07-08 Lanxess Deutschland Gmbh Leichtbauteil in Hybridbauweise
DE202008015401U1 (de) 2008-11-19 2010-04-08 Lanxess Deutschland Gmbh Sitzstrukturen
DE202008015394U1 (de) 2008-11-19 2010-04-08 Lanxess Deutschland Gmbh Längsträgerstruktur
DE202008015392U1 (de) 2008-11-19 2010-04-08 Lanxess Deutschland Gmbh Pedalstruktur
DE202008015396U1 (de) 2008-11-19 2010-04-08 Lanxess Deutschland Gmbh Fahrwerkstruktur
DE202008015400U1 (de) 2008-11-19 2010-04-08 Lanxess Deutschland Gmbh Instrumententafel
DE202008015398U1 (de) 2008-11-19 2010-04-08 Lanxess Deutschland Gmbh Ölwanne
DE102009005763A1 (de) 2009-01-23 2010-07-29 Lanxess Deutschland Gmbh Rahmenseitenteil einer Kraftfahrzeug Karosserie
ATE522568T1 (de) 2009-03-27 2011-09-15 Lanxess Deutschland Gmbh Glühdrahtbeständige polyester
DE102009020090A1 (de) 2009-05-06 2010-11-11 Lanxess Deutschland Gmbh Reduktion des Einflusses der Wasseraufnahme auf die elektrische Leitfähigkeit von elektrisch leitfähigen Polyamid-Formmassen
DE102009034767A1 (de) * 2009-07-25 2011-01-27 Lanxess Deutschland Gmbh & Co. Kg Organoblechstrukturbauteil
US7964594B1 (en) * 2009-12-10 2011-06-21 Hoffmann-La Roche Inc. Amino oxazine derivatives
UA103272C2 (uk) * 2009-12-11 2013-09-25 Ф. Хоффманн-Ля Рош Аг 2-аміно-5,5-дифтор-5,6-дигідро-4h-оксазини як інгібітори bace1 і/або bace2
DE102010053483A1 (de) 2010-12-04 2012-06-06 Lanxess Deutschland Gmbh =N=C=N- enthaltende Verbindung zur Verhinderung des thermischen Abbaus in Schmelzen
EP2365028B1 (de) 2010-03-10 2012-10-03 LANXESS Deutschland GmbH -N=C=N- enthaltende Verbindungen zur Verhinderung des thermischen Abbaus von Metall-dialkylphosphinat enthaltenden Polyalkylenterephthalaten in der Schmelze
CN102190866A (zh) 2010-03-10 2011-09-21 朗盛德国有限责任公司 用于在熔融物中防止热降解的包括-n=c=n-的化合物
EP2463338B1 (de) 2010-12-13 2013-08-28 LANXESS Deutschland GmbH Verfahren zur Optimierung des Kristallisationsverhaltens von Polyester Formmassen
EP2465896A1 (de) 2010-12-14 2012-06-20 LANXESS Deutschland GmbH Polyester Zusammensetzungen
US20140178479A1 (en) * 2011-08-12 2014-06-26 Perosphere, Inc. Concentrated Felbamate Formulations for Parenteral Administration
EP2818297B1 (de) 2013-06-25 2016-08-10 LANXESS Deutschland GmbH Spritzgießverfahren
DE102014000613A1 (de) 2014-01-18 2015-07-23 Lanxess Deutschland Gmbh Polyester Zusammensetzungen
EP2878625A1 (de) 2013-11-27 2015-06-03 LANXESS Deutschland GmbH Polyester Zusammensetzungen
IN2014DE03298A (de) 2013-11-27 2015-09-25 Lanxess Deutschland Gmbh
PL2878628T3 (pl) 2013-11-27 2017-08-31 Lanxess Deutschland Gmbh Kompozycje poliestrów
DE102014000612A1 (de) 2014-01-18 2015-07-23 Lanxess Deutschland Gmbh Polyester Zusammensetzungen
EP2878626B1 (de) 2013-11-27 2021-10-27 LANXESS Deutschland GmbH Verwendung von polyester-zusammensetzungen
HUE047680T2 (hu) 2013-11-28 2020-05-28 Lanxess Deutschland Gmbh Poliamid-kompozíciók
EP2915841A1 (de) 2014-03-04 2015-09-09 LANXESS Deutschland GmbH Polyester Zusammensetzung
HUE039596T2 (hu) 2014-05-05 2019-01-28 Lanxess Deutschland Gmbh Poliészter vegyületek

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2884444A (en) * 1956-01-13 1959-04-28 Carter Prod Inc 2-phenyl-1,3 propane diol dicarbamate
US4161582A (en) * 1976-11-22 1979-07-17 Hoffman-La Roche Inc. Process to produce oxazinomycin
US4384115A (en) * 1981-12-14 1983-05-17 The Dow Chemical Company Process for preparing tetrahydro-1,3-oxazin-2-ones
US4868327A (en) 1987-06-03 1989-09-19 Carter-Wallace, Inc. Synthesis of 2-phenyl-1,3-propanediol
US4978680A (en) 1989-09-26 1990-12-18 Carter-Wallace, Inc. Method for the prevention and control of epileptic seizure
US5082861A (en) 1989-09-26 1992-01-21 Carter-Wallace, Inc. Method for the prevention and control of epileptic seizure associated with complex partial seizures
US5292772A (en) 1989-09-26 1994-03-08 Carter-Wallace, Inc. Method for the prevention and control of epileptic seizure associated with Lennox-Gastaut syndrome
US5055489A (en) 1990-05-04 1991-10-08 Carter-Wallace, Inc. Method for the prevention and control of hypoxic damage resulting from cerebral ischemic events
IL107002A0 (en) * 1992-09-18 1993-12-28 Avondale Chem Corp Process for preparing felbamate and intermediates thereof
US5462966A (en) 1993-10-15 1995-10-31 Carter-Wallace Inc. Methods for the prevention and control of cellular damage resulting from coronary artery occlusion-reperfusion
US5492930A (en) * 1994-04-25 1996-02-20 Schering Corporation Method and formulation for treating CNS disorders
US5728728A (en) 1996-04-10 1998-03-17 Kozachuk; Walter E. Methods of providing neuroprotection

Also Published As

Publication number Publication date
DE60003791D1 (de) 2003-08-14
JP2002536409A (ja) 2002-10-29
EP1156798B1 (de) 2003-07-09
MXPA01007968A (es) 2003-07-14
PT1156798E (pt) 2003-11-28
CA2360258A1 (en) 2000-08-17
AU2873400A (en) 2000-08-29
US6599935B2 (en) 2003-07-29
US6538024B1 (en) 2003-03-25
EP1156798A4 (de) 2002-07-17
AU771936B2 (en) 2004-04-08
US20020156070A1 (en) 2002-10-24
ES2197078T3 (es) 2004-01-01
US6759402B2 (en) 2004-07-06
US20030229086A1 (en) 2003-12-11
DE60003791T2 (de) 2004-02-05
NZ513319A (en) 2003-08-29
WO2000047202A1 (en) 2000-08-17
DK1156798T3 (da) 2003-11-03
EP1156798A1 (de) 2001-11-28

Similar Documents

Publication Publication Date Title
DE60003791D1 (de) Felbamat-derivate
TR200201505T2 (tr) Terapötik maddeler olarak pirazolopirimidinler
ECSP003610A (es) Pirimidina-2,4,6 trionas inhibidores de metaloproteinas
TR199901904T2 (xx) 3-piridil enantiyomerleri ve bunlar�n analjezik olarak kullan�lmas�.
DE60126980D1 (de) Therapeutische agentien und methoden ihrer verwendung zur behandlung von amyloidogenen erkrankungen
ES2119124T3 (es) Bencimidazoles utiles para el tratamiento de trastornos del sistema nervioso.
PA8481301A1 (es) Derivados de 4,4-biarilpiperidina
TR200401545T4 (tr) NOSS inhibitörü ilaçların amalatı için ikame imidazo [1,2-a]piridin-,-pirimidin- ve-pirazin-3-amin-türevlerinin kullanımı
ATE324444T1 (de) Tek-antagonisten
ATE277929T1 (de) Immunsuppressive wirkungen von pteridinderivaten
DE60144277D1 (de) Hemmer der menschlichen phosphatidyl-inositol-3-kinase delta
UY26130A1 (es) Compuestos para tratar la obesidad
ES2168359T3 (es) Acido micofenolico 6-sustituido y derivados con actividad inmunosupresora.
MXPA04006184A (es) Compuestos derivados de 1h-pirazolilo, para el uso en enfermedades asociadas con el receptor 5-ht2c.
BR0212617A (pt) Compostos de pirazolila substituìdo para o tratamento de inflamação
MY119375A (en) Treatment of tinnitus using neuroprotective agents
CR6824A (es) Derivados de arilmetilamina para uso como inhibidores de triptasa
DK1032556T3 (da) Farmaceutisk aktive forbindelser og anvendelsesfremgangsmåder
DE60016181D1 (de) C-16 ungesätigte fp-selektive prostaglandin analoge
ES2064119T3 (es) Nuevos derivados de aminobenzosultam como inhibidores de la lipoxigenasa.
DE60026491D1 (de) Melagatran zur behandlung von entzündungen
EE05241B1 (et) Distamtsiini a-halogenoakrlolderivaadi kasutamine
ECSP003590A (es) Compuestos calcioliticos
YU58601A (sh) Derivati fenilalaninola
ES2118248T3 (es) Esteres y amidas de 9-cloro-prostaglandina y su empleo para preparar medicamentos.

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1156798

Country of ref document: EP

REN Ceased due to non-payment of the annual fee